ImmunityBio, Inc. (NASDAQ:IBRX) Shares Acquired by State Street Corp

State Street Corp increased its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 10.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,654,460 shares of the company’s stock after purchasing an additional 790,408 shares during the quarter. State Street Corp’s holdings in ImmunityBio were worth $32,195,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of IBRX. HighTower Advisors LLC purchased a new position in shares of ImmunityBio in the 3rd quarter valued at about $136,000. Verition Fund Management LLC lifted its stake in ImmunityBio by 131.8% in the third quarter. Verition Fund Management LLC now owns 94,270 shares of the company’s stock worth $351,000 after acquiring an additional 53,607 shares during the last quarter. Captrust Financial Advisors acquired a new position in ImmunityBio during the 3rd quarter worth approximately $41,000. Quantbot Technologies LP purchased a new stake in shares of ImmunityBio in the 3rd quarter valued at approximately $143,000. Finally, Advantage Alpha Capital Partners LP acquired a new stake in shares of ImmunityBio in the 3rd quarter valued at $257,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Trading Down 1.9 %

Shares of ImmunityBio stock opened at $2.62 on Friday. The company has a fifty day simple moving average of $4.49 and a 200-day simple moving average of $4.74. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -2.85 and a beta of 0.86. ImmunityBio, Inc. has a 12-month low of $2.61 and a 12-month high of $10.53.

Analyst Upgrades and Downgrades

IBRX has been the topic of several recent analyst reports. D. Boral Capital reissued a “buy” rating and issued a $30.00 target price on shares of ImmunityBio in a report on Friday. EF Hutton Acquisition Co. I upgraded ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.